Hypersomnia in anti‐glutamic acid decarboxylase 65 ( GAD65 ) associated neurological syndromes: A pilot study
European Journal of Neurology · 2024
DOI: 10.1111/ene.16125 ↗Kurz gefasst
Fachartikel in der Zeitschrift European Journal of Neurology, 2024. Verfasst von Lina Jeantin und 11 weiteren Autor:innen. Beteiligte Einrichtung: Sleep Disorders Unit, R3S Department, Pitié-Salpêtrière Hospital, AP-HP Sorbonne University, Paris, France. Hauptthemen laut MEDLINE: Disorders of Excessive Somnolence, Carboxy-Lyases. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 15 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).
Abstract (Originalsprache)
Background and purpose Despite their detrimental impact on the quality of life in autoimmune encephalitis, sleep disorders have not been investigated in anti‐glutamic acid decarboxylase (GAD65) associated neurological syndromes.
Methods
Six consecutive adult patients diagnosed with anti‐GAD65‐associated neurological syndromes (four with limbic encephalitis and two with stiff‐person syndrome) and 12 healthy controls were enrolled. Participants underwent sleep interviews and sleep studies including night‐time video‐polysomnography, followed by five daytime multiple sleep latency tests (MSLTs, to assess propensity to fall asleep) and an 18 h bed rest polysomnography (to assess excessive sleep need).
Results
Patients reported the need for daily naps and that their cognition and quality of life were altered by sleepiness, but they had normal scores on the Epworth sleepiness scale. Compared with controls, sleep latencies during the MSLT were shorter in the patient group (median 5.8 min, interquartile range [IQR] 4.5, 6.0 vs. 17.7 min, IQR 16.3, 19.7, p = 0.001), and the arousal index was reduced (2.5/h, IQR 2.3, 3.0 vs. 22.3/h, IQR 13.8, 30.0, p = 0.002), although total sleep time was similar between groups (621 min, IQR 464, 651 vs. 542.5 min, IQR 499, 582, p = 0.51). Remarkably, all six patients had MSLT latencies ≤8 min, indicating severe sleepiness. No parasomnia or sleep‐disordered breathing was detected.
Conclusion
Central hypersomnia is a relevant characteristic of anti‐GAD65‐associated neurological syndromes.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Sleep Disorders Unit, R3S Department, Pitié-Salpêtrière Hospital, AP-HP Sorbonne University, Paris, France.
- Neuro-Oncology Unit, Neurology Department, Pitié-Salpêtrière Hospital, AP-HP Sorbonne University, Paris, France.
- Movement Disorder Unit, Neurology Department, Pitié-Salpêtrière Hospital, Paris, France.
ORCID-Profile: Lina Jeantin, Ana Gales
Zitieren
APA
Jeantin, L., Gales, A., Berzero, G., Leu, S., Proust, J., Giry, M., Valyraki, N. E., Birzu, C., Alentorn, A., Vidailhet, M., Psimaras, D., & Arnulf, I. (2024). Hypersomnia in anti‐glutamic acid decarboxylase 65 ( GAD65 ) associated neurological syndromes: A pilot study. European Journal of Neurology. https://doi.org/10.1111/ene.16125
Vancouver
Jeantin L, Gales A, Berzero G, Leu S, Proust J, Giry M, et al. Hypersomnia in anti‐glutamic acid decarboxylase 65 ( GAD65 ) associated neurological syndromes: A pilot study. European Journal of Neurology. 2024. doi:10.1111/ene.16125
BibTeX
@article{Jeantin2024,
author = {Jeantin, Lina and Gales, Ana and Berzero, Giulia and Leu, Smaranda and Proust, Jérémy and Giry, Marine and Valyraki, Nefeli Eirini and Birzu, Cristina and Alentorn, Agusti and Vidailhet, Marie and Psimaras, Dimitri and Arnulf, Isabelle},
title = {Hypersomnia in anti‐glutamic acid decarboxylase 65 ( GAD65 ) associated neurological syndromes: A pilot study},
journal = {European Journal of Neurology},
year = {2024},
doi = {10.1111/ene.16125}
}
EUVIMED